Glaxo SmithKline OTC Switch Potential Seen As Merger Catalyst
This article was originally published in The Tan Sheet
Executive Summary
The Rx influenza treatment Relenza tops the list of potential OTC switch candidates in the Glaxo SmithKline portfolio, according to merger details announced the week of Jan. 17.
You may also be interested in...
GlaxoSmithKline Merger Completion Delayed To Year-End
The planned merger of SmithKline Beecham and Glaxo Wellcome will be delayed, likely until the end of the year, due to continued Federal Trade Commission inquiries.
GlaxoSmithKline Merger Completion Delayed To Year-End
The planned merger of SmithKline Beecham and Glaxo Wellcome will be delayed, likely until the end of the year, due to continued Federal Trade Commission inquiries.
GlaxoSmithKline Merger Completion Delayed To Year-End
The planned merger of SmithKline Beecham and Glaxo Wellcome will be delayed, likely until the end of the year, due to continued Federal Trade Commission inquiries.